About Twist Bioscience Corporation

Twist Bioscience Corporation, founded in 2013, has pioneered high-throughput DNA synthesis technology that enables rapid, cost-effective production of synthetic DNA for research, therapeutics development, and industrial applications. The company has built the industry's leading synthetic DNA platform. TWST stock price reflects both the company's technology leadership and the growing applications for synthetic biology.

Led by CEO Emily Leproust, who co-founded the company, Twist Bioscience has successfully commercialized its DNA synthesis platform while expanding into new applications including data storage and therapeutic antibody discovery. The management team combines expertise in synthetic biology with proven business execution capabilities. Leadership's vision for enabling synthetic biology applications through innovative DNA synthesis has been instrumental in building market leadership and influencing TWST stock price trajectory.

Twist Bioscience operates by providing synthetic DNA products including genes, oligonucleotides, and clonal libraries to customers in pharmaceuticals, agriculture, chemicals, and academic research using its proprietary silicon-based DNA synthesis platform. The company generates revenue from product sales and collaborations while building capabilities in therapeutic applications. With synthetic biology enabling innovation across multiple industries, growing demand for custom DNA products in drug discovery and development, and Twist Bioscience's established technology platform and market leadership, TWST offers investors exposure to the synthetic biology revolution with significant growth potential as synthetic DNA applications continue expanding across healthcare and industrial markets.